Substitution of Dolutegravir for Raltegravir 1200 mg QD in HIV-infected patients who develop neuropsychiatric symptoms after initiating triple therapy. Pilot clinical study (Neuropsiquiatric Evolution After Introduction of Raltegravir QD in subs
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: PUBLIC ANDALUSIAN FOUNDATION FOR RESEARCH OF MALAGA IN BIOMEDICINE AND HEALTH
- Phase: IV
- Execution start: 23/07/2020
- End of execution: 30/06/2022
- PI: CARMEN HIDALGO TENORIO